Lo.Li. Pharma International announced a new strategic partnering plan for their new product, Deplesin, which meets a huge unmet need for bipolar disorder (BD) patients, while emphasizing corporate commitments to innovation and increasing partner revenue. International partnership discussions are already underway, with the aim of increasing accessibility to this novel adjunctive agent in the treatment of BD patients, who often experience a number of unpleasant and long-term side effects associated with primary pharmacotherapy.

"Millions of bipolar patients around the world are experiencing unnecessary, and often embarrassing side effects from their primary pharmacological treatments," said Samanta De Filippi, General Manager of Lo.Li. Pharma International. "Our Founder, global inositol expert Vittorio Unfer, MD, developed Deplesin as an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine to support patients in ways that prescription medications often cannot; in this case, to alleviate primary treatment side effects which lead to drug abandonment or poor quality of life."

Lo.Li. Pharma International is focused on building strategic partnerships with companies who are committed to providing innovative options to bipolar patients and psychiatrists, and who are already well-versed in the neuropsychiatric therapeutic area.

De Filippi said, "With over 15 years of commercialization experience in the local Italian market, we know how difficult it can be to remain competitive in a crowded industry. Imagine bringing a completely novel product to market, which almost all BD patients truly need."

While many drugs have been approved since the introduction of lithium in the 1970's, which is still considered the gold-standard treatment for most BD patients, there is still a huge unmet need for patients who are experiencing these concerning side effects. While it may not garner as much attention as a traditional, blockbuster pharmaceutical drug would, Deplesin offers a new solution to a problem that has been largely unaddressed for decades.